Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Alise Lombardo"'
Autor:
Alise Lombardo, Andrew Schumacher, Kayla Rosati, Nathan T. Connell, Peter Barth, Mary Anne Fenton, Katherine E. Faricy-Anderson, Rouba Youssef, Anthony George Thomas, Anthony Mega, Howard Safran, Humera Khurshid, Emmanuel Apor, William M. Sikov, Susan Korber
Publikováno v:
Clinical Journal of Oncology Nursing. 22:76-82
Background Patients with cancer experience stress surrounding diagnosis and treatment. Many cancer centers employ a nurse-led education session to alleviate patient anxiety and confusion. . Objectives The goal was to evaluate the effect of a nurse-le
Autor:
John L. Reagan, Adam J. Olszewski, Alessandro Papa, Pamela Bakalarski, Kalyan Mantripragada, Rachael Rossiter, Anthony Mega, Carolyn Bartley, Alise Lombardo, Ariel E. Birnbaum, Howard Safran, Andrew Schumacher, Kimberly Perez, Humera Khurshid
Publikováno v:
Journal of Oncology Practice. 12:e396-e404
Purpose: Successful clinical trial accrual targeting uncommon genomic alterations will require broad national participation from both National Cancer Institute (NCI)–designated comprehensive cancer centers and community cancer programs. This report
Autor:
Andrew Schumacher, Howard Safran, Carolyn Bartley, Brittany Cammisa, Alise Lombardo, Cynthia Leach, Denise Luppe, Rachael Rossiter, Kayla Rosati
Publikováno v:
Journal of Clinical Oncology. 33:e17702-e17702
Autor:
Kalyan Mantripragada, Kenneth D. Bishop, Kayla Rosati, Lynn Shaw, Trevor Clark Austin, Kristen Mitchell, Kimberly Perez, Lindsay Houlihan, Alise Lombardo, Howard Safran, Kevin P. Charpentier, Diane Martel
Publikováno v:
Journal of Clinical Oncology. 32:4123-4123
4123 Background: The contribution of irinotecan to the efficacy of FOLFIRINOX in pancreatic cancer is uncertain. The addition of irinotecan to gemcitabine was not superior to gemcitabine alone in p...
Autor:
Kayla Rosati, Lindsay Houlihan, Kevin P. Charpentier, Lucia Fontes-Borts, Irene Kolberg, Kristen Mitchell, Omar Nadeem, Kalyan Mantripragada, Alise Lombardo, Trevor Clark Austin, Kimberly Perez, Howard Safran
Publikováno v:
Journal of Clinical Oncology. 32:258-258
258 Background: FOLFIRINOX improves survival in advanced pancreatic cancer, however the contribution of irinotecan is uncertain. The addition of irinotecan to gemcitabine was not superior to gemcitabine alone in pancreatic cancer, however nab-P demon